SUSTAINED RELEASE ARTEMETHER-LOADED SOLID LIPID MICROPARTICLES, BASED ON SOLIDIFIED REVERSE MICELLAR SOLUTION (SRMS)
Objectives: To prepare and evaluate sustained release artemether-loaded SLMs based on SRMS
Material and methods: SRMS, consisting of mixtures of PhospholiponÂ® 90H (P90H) and SoftisanÂ® 154 (1:1, 2:1 and 1:2) were formulated and characterized using differential scanning calorimetry (DSC). The SRMS were used to formulate artemether-loaded SLMs by melt homogenization. The SLMs were characterized based on particle size and morphology, pH stability, encapsulation efficiency (EE%) and loading capacity. In vitro release was carried out in simulated intestinal fluid (SIF, pH 7.5).
Results: Thermograms of the SRMS (1:1, 2:1 and 1:2) showed sharp endothermic peaks at 65.5, 64.4 and 62.3 oC respectively. Maximum EE% of 70.00 Â± 1.50 % was obtained for SLMs formulated with SRMS 1:1 and 1 % artemether. Loading capacity ranged from 5.67 to 17.90 g drug/100 g lipid. In vitro release showed about 80 to 84 % drug release at 7 h. Particle size of artemether-loaded SLMs ranged from 18.60 Â± 0.09 to 34.80 Â± 0.30 Âµm. The pH decreased significantly at 60 days from 6 to 4.8 for batch A2 formulated with SRMS 2:1 and 3 % artemether (p < 0.05).
Conclusion: artemether-loaded SLMs based on SRMS had good sustained release properties and could be used once daily in order to enhance patientâ€™s compliance.
Key words: Malaria, artemether, SRMS, lipids, sustained release SLMs
2. Li Q and Weina P. Artesunate: The best drug in the treatment of severe and complicated malaria. Pharmaceuticals 2010; 3:2322-2332. Doi:10.3390/ph3072322.
3. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002; (415): 670-672.
4. World Health Organization, 2006. Guidelines for the Treatment of malaria (1st ed) World Malaria Report WHO/HTM/MAL/2006.1108.WHO, Geneva.
5. Nosten F, White NJ.Artemisinin-based combination treatment of falciparum malaria. Amer J Trop Med Hyg 2007; 77(6):181-192.
6. Santos-Magalhaes NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010; 62:560-575.
7. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341:603â€“608.
8. Suputtamongkol Y, Newton PN, Brian A, Teja-Isavadharm P, Keeratithakul D, Rasameesoraj M, Pukrittayakamee S and White NJ. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol 2001; 52(6): 655â€“661.
9. White NJ. Malaria. In: Cook G, ed. Manson's Tropical Diseases. London: W.B. Saunders 1996; pp. 1087â€“1164.
10. Lindegardh N, Hampithakong W, Kamanikom B, Singhasivanon P, Socheat D, Yi P, Dondorp AM, McGready R, Nosten F, White NJ, Day NPJ. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B 2008; 876:54-60.
11. Thanh NV, Cowman AF, Hipgrave D, Kim TB, Phuc BQ, Cong LD, Biggs BA. Assessment of susceptibility of Plasmodium falciparum to chloroquine, quinine, mefloquine, sulphadoxine-pyrimethamine and artemisinin in Southern Vietnam. Trans Royal Soc Trop Med Hyg 2009; 95:513-517.
12. Semete B, Kalombo L, Katata L, Swai H. Nano-drug Delivery Systems: Advances in TB, HIV and malaria treatment. Smart Biomol Med 2010: 15-52.
13. Obonyo CO, Juma EA, Ogutu BR, Vulude JM, Lau J. Amodiaquine combined with sulphadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: A meta-analysis. Trans Roy Trop Med Hyg 2007; 101:117-126.
14. Joshi M, Pathak S, Sharma S, Patravale V. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int J Pharm 2008; 362: 172-8.
15. Schneeweis A, Muller-Goymann CC. Controlled release of solid-reversedmicellar-solution (SRMS) suppositories containing metoclopramide-HCl. Int J Pharm 2000; 196:193â€“196.
16. Friedrich I, Muller-Goymann CC. Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMSbased nanosuspensions. Eur J Pharm Biopharm 2003;56:111â€“119.
17. Chime SA, Attama AA, Builders PF, Onunkwo GC. Sustained release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: In vitro and in vivo evaluation. J Micro 2012; 1â€“11. DOI: 10.3109/02652048.2012.726284.
18. Chime SA, Attama AA, Onunkwo GC. Sustained release indomethacin-loaded solid lipid microparticles, based on solidified reverse micellar solution (SRMS): in vitro and in vivo evaluation. J Drug Del.Sci Tech 2012; 22(5):485-492.
19. Chime SA, Attama AA, Kenechukwu FC, Umeyor EC, Onunkwo GC (2013). Formulation, in vitro and in vivo characterisation of diclofenac potassium sustained release tablets based on solidified reverse micellar solution (SRMS). Brit J Pharm Res 2013; 3(1): 90-107.
20. Umeyor EC, Kenechukwu FC, Ogbonna JD, Chime SA and Attama AA. Preparation of novel solid lipid microparticles loaded with gentamicin and its evaluation in vitro and in vivo. J. Microencapsul 2012; 1- 12. DOI: 10.3109/02652048.2011.651495.
21. Attama AA, Okafor CE, Builders PF, Okorie O. Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium. Drug Deliv 2009; 16:448 â€“ 616.
22. Singh J, Gupta S, Kaur H. Prediction of in vitro drug release mechanisms from extended release matrix tablet using SSR/SR2 techniques. Trends in App Sci Res 2011; 6(4):400 â€“ 409.
23. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattera EB. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS Pharm Sci Technol 2004; 5(2), e27(Article 27).
24. Jaspart S, Piel G, Delatte L, Evrad B. Solid lipid microparticles: Formulation, preparation, characterization, drug release and applications. Expert Opin Drug Deliv 2005; 2:75â€“87.
25. El-Kamel HA, Alâ€“Fagih MI, Alsarra AI. Testosterone solid lipid microparticles for transdermal drug delivery formulation and physicochemical characterisation. J Microencapsul 2007; 24(5):457â€“75.
26. Attama AA and Muller-Goymann CC. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid. Int J Pharm 2007; 334:179â€“89.
27. Attama AA, Schicke BC, MÃ¼ller-Goymann CC. Further characterization of theobroma oil beeswax admixtures as lipid matrices for improved drug delivery systems. Eur J Pharm Biopharm 2006; 64:294-306.
28. Khopade AJ, Jain NK. Long circulating lipospheres targeted to inflamed tissue. Pharmazie 1997; 52:165-166.
29. Higuchi T. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52:1145-1149.
30. Ritger PL and Peppas NA. A simple equation for description of solute release 1. Fickian and non- Fickian release from non swellable device in the form of slabs, spheres, cylinders and discs. J Cont Rel 1987; 5:23-36.